| Literature DB >> 31500180 |
Anna K King1, Kara McGill-Meeks2, Jennifer P Beller3, Christine M Burt Solorzano4,5.
Abstract
Weight loss can reduce the hyperandrogenemia associated with polycystic ovary syndrome (PCOS) in peripubertal girls. Yet, adolescent girls have the lowest rates of physical activity and enjoyment of exercise. We created a dance-based support group (Go Girls!) to entice physical activity and improve enjoyment. Girls ages 7-21 over the 85th BMI percentile were recruited and attended once-weekly sessions for 3-6 months. We assessed changes in Physical Activity Enjoyment Scale (PACES), anthropometrics, laboratory data, and amounts of home exercise at 0, 3, and 6 months. Sixteen girls completed either 3 or 6 months. PACES scores were surprisingly high at baseline and remained high. Systolic blood pressure percentile decreased post-intervention. Although no group differences were observed, the majority of individual girls had decreased waist circumference, triglycerides, and metabolic syndrome severity score. Forty percent had decreased free testosterone levels. More girls enjoyed physical education class, got exercise outside of school, and made other lifestyle changes. This dance-based support group was enjoyed by girls and demonstrated health benefits. Continued efforts to engage girls in physical activity are necessary to protect girls from the consequences of obesity, including PCOS and metabolic syndrome. Dance exercise remains a promising tool to encourage physical activity in girls.Entities:
Keywords: Zumba; childhood obesity; dance; polycystic ovary syndrome
Year: 2019 PMID: 31500180 PMCID: PMC6769571 DOI: 10.3390/children6090099
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1Subjects recruited and retained.
Baseline and post-program subject data.
| Enrolled | Pre | Post | |
|---|---|---|---|
| N | 28 (14) | 16 (9) | |
| Age (y) | 13.1 ± 2.7 | 12.6 ± 3.0 | |
| Race/Ethnicity (%) | |||
| White | 60 | 74 | |
| Black | 29 | 25 | |
| Hispanic | 11 | 1 | |
| PACES (max 5) | 4.03 ± 1.01 | 3.88 ± 1.25 | 4.12 ± 1.07 |
| Body Mass Index (kg/m2) | 33.6 ± 7.3 | 32.4 ± 6.9 | 32.9 ± 7.1 |
| Body Mass Index (%-ile) | 98.2 ± 2.6 | 97.8 ± 3.2 | 96.6 ± 8.0 |
| Systolic Blood Pressure (mmHg) | 120.2 ± 13.4 | 122.6 ± 15.9 | 117.8 ± 19.4 |
| Systolic Blood Pressure (%-ile) | 76.8 ± 23.3 | 80.3 ± 26.0 | 66.9 ± 33.5 * |
| Waist circumference (cm) | 105.9 ± 17.0 | 104.8 ± 16.3 | 103.0 ± 17.0 |
| Free Testosterone (pmol/L) | 23.1 ± 21.9 | 26.1 ± 26.0 | 33.2 ± 36.0 |
| DHEA-S (µmol/L) | 3.99 ± 3.38 | 2.78 ± 1.98 | 2.80 ± 2.34 |
| HDL (mmol/L) | 1.05 ± 0.17 | 1.02 ± 0.14 | 1.01 ± 0.19 |
| LDL (mmol/L) | 2.29 ± 0.58 | 2.42 ± 0.68 | 2.36 ± 0.65 |
| Triglycerides (mmol/L) | 1.21 ± 0.65 | 1.34 ± 0.74 | 1.38 ± 0.82 |
| HbA1c (%) | 5.49 ± 0.30 | 5.38 ± 0.28 | 5.29 ± 0.35 |
| Insulin (pmol/L) | 199.0 ± 110.6 | 208.0 ± 129.3 | 233.3 ± 126.4 |
| Glucose (mmol/L) | 4.77 ± 0.45 | 4.55 ± 0.30 | 4.69 ± 0.35 |
| HOMA-IR | 6.09 ± 3.24 | 5.95 ± 3.88 | 6.80 ± 4.18 |
| Metabolic Syndrome Severity (z) | 1.374 ± 0.463 | 1.375 ± 0.448 | 1.294 ± 0.715 |
“N” is represented as total subjects (subjects with lab values). Data are mean ± SD, except race/ethnicity (%). * p < 0.05. SI to U.S. units: free testosterone pg/mL = pmol/L * 0.2882; DHEA-S µg/dL = µmol/L * 36.9; HDL and LDL mg/dL = mmol/L * 38.61; triglycerides mg/dL = mmol/L * 88.5; insulin µIU/mL = pmol/L * 0.1440; glucose mg/dL = mmol/L * 18. Conversion formulas to SI units from Quest Diagnostics.
Figure 2Individual results.
Prevalence of metabolic syndrome pre- and post-intervention.
| Parameter | Enrolled | Pre | Post |
|---|---|---|---|
| N = 14 | N = 9 | ||
| Elevated blood pressure (SBP > 90th%-ile) | 7 (50) | 5 (56) | 3 (33) |
| Obesity (WC > 90th%-ile) | 14 (100) | 9 (100) | 8 (89) |
| Glucose intolerance (Fasting glucose ≥ 110 mg/dL [6.11 mmol/L]) | 0 (0) | 0 (0) | 0 (0) |
| Dyslipidemia (Triglycerides ≥ 110 mg/dL [1.24 mmol/L]) | 6 (43) | 5 (56) | 3 (33) |
| Dyslipidemia (HDL-C ≤ 40 mg/dL [1.04 mmol/L]) | 8 (57) | 6 (66) | 5 (56) |
| Subjects with metabolic syndrome * (≥3 risk factors) | 7 (50) | 6 (66) | 2 (22) |
Data are presented as number of subjects (%). * Based on definition of pediatric metabolic syndrome by Cook et al., 2003. No significant difference in prevalence pre- versus post-intervention (p = 0.07).